Not available
Quote | Cara Therapeutics Inc. (NASDAQ:CARA)
Last: | $0.3445 |
---|---|
Change Percent: | -0.86% |
Open: | $0.35 |
Close: | $0.3445 |
High: | $0.3549 |
Low: | $0.338 |
Volume: | 337,384 |
Last Trade Date Time: | 07/19/2024 03:00:00 am |
News | Cara Therapeutics Inc. (NASDAQ:CARA)
Gainers: Burning Rock Biotech ( BNR ) +4% . TripAdvisor ( TRIP ) +2% . comScore ( SCOR ) +2% . Arrowhead Pharmaceuticals ( ARWR ) +2% . Bolt Biotherapeutics ( BOLT ) +2% . Losers: Swvl Holdings ( SWVL ) ...
Commercial-stage biopharma, Cara Therapeutics ( NASDAQ: CARA ) announced on Thursday that the company’s lead product difelikefalin reached the primary endpoint in a Phase 2 trial designed to evaluate it in pruritus in patients with notalgia paresthetica (NP). NP is ...
Message Board Posts | Cara Therapeutics Inc. (NASDAQ:CARA)
Subject | By | Source | When |
---|---|---|---|
Yeah, good entry room for upwards momentum? | WallStreetMyWay | investorshub | 04/12/2022 4:05:19 PM |
Moving up saved its nice growing money nows | WallStreetMyWay | investorshub | 04/12/2022 4:02:57 PM |
Got some bounce today. | a surfer | investorshub | 03/02/2022 9:15:22 PM |
https://www.benzinga.com/news/earnings/21/11/24060763/you-ask-we-analyze-why-sun | BottomBounce | investorshub | 11/16/2021 4:03:01 PM |
$CARA chart | conix | investorshub | 11/15/2021 11:25:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Cara Therapeutics Inc. Company Name:
CARA Stock Symbol:
NASDAQ Market:
Cara Therapeutics Inc. Website:
– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieve...
KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease...
STAMFORD, Conn., May 03, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President an...